Reporter Seongmin Kim, Bio Spectator
Promoting a special listing of technology. The listing organizer is Hana Financial Investment and Mirae Asset Daewoo
NeoImmunetech passed the preliminary examination for listing on the KOSDAQ. The company is pursuing a technology special listing, and the listing organizers are Hana Financial Investment and Mirae Asset Daewoo.
Neoimmuntech said, “After preparing all the matters, we plan to quickly submit a stock report and initiate the public offering procedure for IPO,” and “plan to list on the KOSDAQ early next year.”
Founded in 2014, Neo-Imuntech is a biotechnology company that researches and develops new T-cell-centered next-generation immune anticancer drugs, and is an affiliate of Genexine, a KOSDAQ listed company. The head office is located in Maryland, the eastern part of the United States, and has a Korean subsidiary in Pangyo and a corporate-affiliated research center within Pohang University.
The main pipeline is the new immune anticancer drug’NT-I7′, a mechanism that induces amplification of T cells, and is expected to have a synergistic effect with existing anticancer drugs. Neo-Imuntech has signed a contract with Big Pharma such as Merck (MSD), BMS, and Roche in the United States to supply immuno-anti-cancer drugs for the clinical trial of NT-I7 co-administration.
Neoimmuntech holds the copyright for all markets in North America, Central America, South America, and Europe, and is currently conducting clinical trials for solid cancer and blood cancer, and plans to expand its indications to rare and infectious diseases.
Yang Se-hwan, CEO of Neoimmuntech said, “After the IPO, we intend to focus on global clinical trials that we are currently pursuing, and through this, we will contribute to the treatment of immune anticancer and infectious diseases by proving the value of differentiated new drugs.” He emphasized, “We will take a further leap forward as a leading company in the market for immunotherapy drugs.”
On the other hand, Neo-Imuntech was recently approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of non-small cell lung cancer with NT-I7 and Roche’s Tecentriq®, a phase 2 clinical trial plan (IND) to begin clinical trials. Is expected. In addition, it started phase 1 clinical trial of Corona 19 last month.